Brought to you by 
ViaCyte gets $10.6mm via Series C-1 financing; adds $5.4mm
15 Aug 2014
Executive Summary
Regenerative medicine company ViaCyte Inc. has raised $10.6mm by selling Series C-1 preferred shares to returning investors Johnson & Johnson Development Corp., Sanderling Ventures, and Asset Management Co. The company also issued warrants. ViaCyte will use the proceeds from the financing to initiate clinical trials--anticipated for the first half of 2014--of its VC01 encapsulated cell therapy candidate for Type I diabetes. ViaCyte was already awarded $10.1mm from CIRM to study VC01.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Gene Therapy, Cell Therapy
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
ViaCyte gets $10.6mm via Series C-1 financing; adds $5.4mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice